Literature DB >> 11748657

Occurrence of hepatitis E virus IgM, low avidity IgG serum antibodies, and viremia in sporadic cases of non-A, -B, and -C acute hepatitis.

J Z Zhang1, Stanley W K Im, S H Lau, T N Chau, S T Lai, S P Ng, Malik Peiris, Cindy Tse, T K Ng, M H Ng.   

Abstract

Serum samples were taken from 57 patients with sporadic non-A, -B, and -C (Non A, B, C) acute hepatitis at different times after onset of the disease and tested for the presence of the hepatitis E virus (HEV) RNA, IgM, and low avidity IgG antibodies. The viral antibodies were detected using two ELISA. One assay (GL) was produced using a mixture of recombinant peptides specified by ORF2 and ORF3 of the viral genome. The other was produced with an ORF2 specified peptide, pE2. The latter occurs naturally as homodimer, it is recognized strongly in its dimeric form by human sera and, in the primate model, it confers protection against experimental HEV infection. Nineteen samples were positive for one or more of these acute markers of HEV infection, 14 of which were acute sera with elevated ALT levels and 5 were convalescent sera with normal ALT level. The results showed that icteric phase of sporadic hepatitis lasts for about 17 days and it coincides with a period when viremia is subsiding as HEV antibodies are developing. Viremia was intermittent and all but one of the 5 instances were confined to the icteric phase with elevated ALT levels. On two of these occasions, viremia preceded detection of HEV antibody, on another 2 occasions it was concurrent with the detection of pE2 specific IgM and/or low avidity IgG and only in one case of protracted viremia was the viral genome detected concurrently with avid pE2 IgG antibody. Ten (71%) of the 14 acute sera were reactive for pE2 IgM, eight (57%) were reactive for low avidity pE2 IgG, and six (43%) for the GL IgM. The sensitivity for the diagnosis of acute hepatitis E may be increased to 87% by combining pE2 IgM and viremia. GL IgM was detected later, but persisted for a longer period of time than the pE2 antibodies, and it was the only acute antibody detected in the convalescent sera. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11748657     DOI: 10.1002/jmv.2109

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  23 in total

1.  Good performance of immunoglobulin M assays in diagnosing genotype 3 hepatitis E virus infections.

Authors:  Florence Legrand-Abravanel; Isabelle Thevenet; Jean-Michel Mansuy; Karine Saune; Françoise Vischi; Jean-Marie Peron; Nassim Kamar; Lionel Rostaing; Jacques Izopet
Journal:  Clin Vaccine Immunol       Date:  2009-03-25

Review 2.  Adaptive Immune Responses in Hepatitis A Virus and Hepatitis E Virus Infections.

Authors:  Christopher M Walker
Journal:  Cold Spring Harb Perspect Med       Date:  2019-09-03       Impact factor: 6.915

3.  Significance of serum IgA in patients with acute hepatitis E virus infection.

Authors:  De-Ying Tian; Yan Chen; Ning-Shao Xia
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

Review 4.  Host immune status and response to hepatitis E virus infection.

Authors:  Lisa J Krain; Kenrad E Nelson; Alain B Labrique
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

5.  Functional epitopes on hepatitis E virions and recombinant capsids are highly conformation-dependent.

Authors:  Bin He; Zhigang Zhang; Xinyuan Zhang; Zimin Tang; Chang Liu; Zizheng Zheng; Shaowei Li; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2020-01-29       Impact factor: 3.452

Review 6.  Autochthonous hepatitis e virus infections: a new transfusion-associated risk?

Authors:  Jens Dreier; David Juhl
Journal:  Transfus Med Hemother       Date:  2013-12-30       Impact factor: 3.747

7.  Synthetic rabbit-human antibody conjugate as a control in immunoassays for immunoglobulin M specific to hepatitis E virus.

Authors:  Kuo Zhang; Lunan Wang; Min Liu; Rui Zhang; Jinming Li
Journal:  Virol J       Date:  2010-05-20       Impact factor: 4.099

8.  Evaluation of anti-hepatitis E virus (HEV) immunoglobulin A in a serological screening for HEV infection.

Authors:  Abeer Elkady; Yasuhito Tanaka; Fuat Kurbanov; Noboru Hirashima; Masaya Sugiyama; Anis Khan; Hideaki Kato; Akihiko Okumura; Masashi Mizokami
Journal:  J Gastroenterol       Date:  2007-11-22       Impact factor: 7.527

9.  Serological immunoassay for detection of hepatitis E virus on the basis of genotype 3 open reading frame 2 recombinant proteins produced in Trichoplusia ni larvae.

Authors:  Nereida Jiménez de Oya; Inmaculada Galindo; Olivia Gironés; Erwin Duizer; José M Escribano; Juan-Carlos Saiz
Journal:  J Clin Microbiol       Date:  2009-08-05       Impact factor: 5.948

10.  Use of serological assays for diagnosis of hepatitis E virus genotype 1 and 3 infections in a setting of low endemicity.

Authors:  M Herremans; J Bakker; E Duizer; H Vennema; M P G Koopmans
Journal:  Clin Vaccine Immunol       Date:  2007-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.